FDA approval of HAVRIX (hepatitis A vaccine, inactivated) for persons aged 1-18 years.

Detalles Bibliográficos
Publicado en:MMWR: Morbidity & Mortality Weekly Report Vol. 54; no. 48; pp. 1235 - 1237
Formato: brief item Journal Article
Publicado: Centers for Disease Control & Prevention (CDC) 12/9/2005
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106380584&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106380584
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01492195
        MMW
      jtl: MMWR: Morbidity & Mortality Weekly Report
      issn: 01492195
      maglogo: N
    pubinfo:
      dt: 12/9/2005
      vid: 54
      iid: 48
      pid: 1493
      pub: Centers for Disease Control & Prevention (CDC)
      place: Atlanta, Georgia
    artinfo:
      ui:
        106380584
        106380584
        2009077140
        106380584
      ppf: 1235
      ppct: 2
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: FDA approval of HAVRIX (hepatitis A vaccine, inactivated) for persons aged 1-18 years.
      aug:
      sug:
        subj:
          Drug Approval
          Hepatitis A Prevention and Control
          United States Food and Drug Administration
          Viral Hepatitis Vaccines
          Adolescence
          Child
          Child, Preschool
          Adolescent: 13-18 years
          Child: 6-12 years
          Child, Preschool: 2-5 years
      pubtype: Academic Journal
      doctype:
        brief item
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N